Annual report pursuant to Section 13 and 15(d)

Acquisitions (Tables)

v3.23.2
Acquisitions (Tables)
12 Months Ended
Jun. 30, 2023
Namocell Inc  
Notes Tables  
Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

Preliminary allocation at acquisition date

​

Adjustments to fair value

​

Final allocation at June 30, 2023

Current assets, net of cash

$

3,248

​

$

​

​

$

3,248

Equipment and other long-term assets

 

405

​

​

​

​

 

405

Intangible assets:

​

​

​

​

​

​

​

​

Developed technologies

 

73,900

​

​

​

​

 

73,900

Tradenames

 

700

​

​

​

​

 

700

Customer relationships

 

900

​

​

​

​

 

900

Non-competition agreement

 

100

​

​

​

​

 

100

Goodwill

 

51,051

​

​

206

​

 

51,257

Total assets acquired

 

130,304

​

​

206

​

 

130,510

​

​

​

​

​

​

​

​

​

Liabilities

 

546

​

​

​

​

 

546

Deferred income taxes, net

 

17,974

​

​

206

​

 

18,180

Net assets acquired

$

111,784

​

$

—

​

$

111,784

​

​

​

​

​

​

​

​

​

Cash paid, net of cash acquired

 

101,184

​

​

​

​

 

101,184

Contingent consideration payable

 

10,600

​

​

​

​

 

10,600

Net assets acquired

$

111,784

​

$

—

​

$

111,784

Asuragen, Inc.  
Notes Tables  
Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed

The aggregate purchase price of the acquisitions was allocated to the assets acquired and liabilities assumed based on their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed for the fiscal year 2021 acquisitions (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

Asuragen

​

Eminence

Current assets, net of cash

$

10,422

​

$

3,145

Equipment and other long-term assets

 

3,762

​

​

1,639

Intangible assets:

​

​

​

​

  

Developed technology

 

107,000

​

​

6,778

In-process research and development

 

22,700

​

​

—

Customer relationships

 

11,700

​

​

2,133

Trade names

 

2,000

​

​

—

Non-competition agreement

 

1,000

​

​

—

Goodwill

 

90,563

​

​

7,848

Total assets acquired

 

249,147

​

​

21,543

​

​

​

​

​

​

Liabilities

 

4,963

​

​

1,436

Deferred income taxes, net

 

10,297

​

​

1,357

Net assets acquired

$

233,887

​

$

18,750

​

​

​

​

​

​

Cash paid, net of cash acquired

 

215,587

​

​

9,765

Contingent consideration payable

 

18,300

​

​

8,985

Net assets acquired

$

233,887

​

$

18,750